A phase II study demonstrated that cetuximab plus docetaxel-based chemoradiotherapy postoperatively in patients with high-risk squamous cell carcinoma of the head and neck led to improved disease-free and overall survival.
The CALGB 369901 trial examined how frailty and older age influence the use of adjuvant hormonal therapy for breast cancer and found that while frailty can deter the start of therapy, frail patients who had started on a regimen were not much more likely to discontinue their treatment early.
Obese women who have breast cancer generally have a worse prognosis compared with their non-obese counterparts. A new randomized study suggests that telephone-based intervention is a safe way to help overweight postmenopausal breast cancer patients with weight loss.
Researchers from Harvard Medical School and Indiana University found that women who had a greater number of nevi may be more likely to develop breast cancer, independent of other breast cancer risk factors.